One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

Elizabeth A. Grammer net worth and biography

Elizabeth Grammer Biography and Net Worth

Insider of Ardelyx

Elizabeth Grammer Esq. serves as Chief Legal and Administrative Officer of the Company. She has served as our General Counsel since May 2014 and formerly served as our vice president responsible for legal affairs from December 2012 until May 2014. From 2006 to December 2012, Ms. Grammer served as an independent outside corporate counsel for public and private biotechnology companies, including Ardelyx from January 2010 until December 2012. From 2001 to 2006, Ms. Grammer served as Vice President and General Counsel of Trine Pharmaceuticals, Inc., a biopharmaceutical company. In addition, Ms. Grammer previously served as independent outside corporate counsel to GelTex Pharmaceuticals, a biopharmaceutical company. Ms. Grammer received a B.A. from Boston University and a J.D. from Stanford Law School.

What is Elizabeth A. Grammer's net worth?: The estimated net worth of Elizabeth A. Grammer is at least $2.01 million as of March 20th, 2024. Ms. Grammer owns 312,993 shares of Ardelyx stock worth more than $2,012,545 as of April 19th. This net worth estimate does not reflect any other investments that Ms. Grammer may own. Additionally, Ms. Grammer receives an annual salary of $623,700.00 as Insider at Ardelyx. Learn More about Elizabeth A. Grammer's net worth.
How old is Elizabeth A. Grammer?: Ms. Grammer is currently 60 years old. There are 5 older executives and no younger executives at Ardelyx. The oldest executive at Ardelyx is Mr. Robert C. Blanks, Chief Regulatory Affairs & Quality Assurance Officer, who is 64 years old. Learn More on Elizabeth A. Grammer's age.
What is Elizabeth A. Grammer's salary?: As the Insider of Ardelyx, Inc., Ms. Grammer earns $623,700.00 per year. There are 4 executives that earn more than Ms. Grammer. The highest earning executive at Ardelyx is Mr. Michael G. Raab, President, CEO & Director, who commands a salary of $1,280,000.00 per year. Learn More on Elizabeth A. Grammer's salary.
How do I contact Elizabeth A. Grammer?: The corporate mailing address for Ms. Grammer and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at [email protected]. Learn More on Elizabeth A. Grammer's contact information.
Has Elizabeth A. Grammer been buying or selling shares of Ardelyx?: Elizabeth A. Grammer has not been actively trading shares of Ardelyx in the last ninety days. Most recently, Elizabeth A. Grammer sold 86,000 shares of the business's stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $7.73, for a transaction totalling $664,780.00. Following the completion of the sale, the insider now directly owns 312,993 shares of the company's stock, valued at $2,419,435.89. Learn More on Elizabeth A. Grammer's trading history.
Who are Ardelyx's active insiders?: Ardelyx's insider roster includes Robert Blanks (Insider), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Michael Raab (CEO), David Rosenbaum (Insider), and Scott Sandell (Major Shareholder). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?: In the last year, insiders at the biopharmaceutical company sold shares 31 times. They sold a total of 643,508 shares worth more than $3,874,269.01. The most recent insider tranaction occured on April, 15th when CEO Michael Raab sold 7,500 shares worth more than $52,950.00. Insiders at Ardelyx own 5.5% of the company. Learn More about insider trades at Ardelyx.
Information on this page was last updated on 4/15/2024.

Elizabeth A. Grammer Insider Trading History at Ardelyx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/20/2024	Sell	86,000	$7.73	$664,780.00	312,993
12/11/2023	Sell	50,000	$5.08	$254,000.00	275,675
11/12/2021	Sell	77,432	$1.12	$86,723.84
12/14/2020	Sell	42,000	$7.30	$306,600.00
4/27/2020	Sell	17,824	$7.47	$133,145.28
12/3/2019	Sell	5,000	$6.80	$34,000.00
11/19/2019	Sell	5,000	$7.00	$35,000.00
8/22/2019	Sell	5,000	$3.50	$17,500.00	116,838
8/19/2019	Sell	5,874	$3.00	$17,622.00	120,890
6/4/2019	Sell	2,520	$2.54	$6,400.80
1/2/2019	Sell	4,920	$1.70	$8,364.00	129,284
11/13/2018	Sell	6,539	$2.84	$18,570.76
9/23/2016	Sell	5,000	$12.00	$60,000.00	1,440
9/19/2016	Sell	6,859	$11.21	$76,889.39
7/22/2015	Sell	2,500	$18.00	$45,000.00
7/15/2015	Sell	10,000	$17.12	$171,200.00
3/2/2015	Sell	1,737	$15.81	$27,461.97

Elizabeth A. Grammer Buying and Selling Activity at Ardelyx

Ardelyx Company Overview

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $6.43

$6.27

$6.56

50 Day Range

MA: $8.20

$6.44

$9.74

2 Week Range

Now: $6.43

$3.16

$10.13

Volume

4,318,190 shs

Average Volume

6,108,526 shs

Market Capitalization

$1.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

Strange new buyer driving up gold

From Stansberry Research | Ad

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

Elizabeth Grammer Biography and Net Worth

What is Elizabeth A. Grammer's net worth?

How old is Elizabeth A. Grammer?

What is Elizabeth A. Grammer's salary?

How do I contact Elizabeth A. Grammer?

Has Elizabeth A. Grammer been buying or selling shares of Ardelyx?

Who are Ardelyx's active insiders?

Are insiders buying or selling shares of Ardelyx?